Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule therapeutics and biologics for central nervous system (CNS) disorders, immunology, and infectious diseases, including biodefense. The company’s pipeline is centered on addressing conditions with significant unmet medical need, such as fibromyalgia, post-traumatic stress disorder (PTSD), and viral threats with pandemic or bioterrorism relevance.
The company’s primary value drivers are its late-stage and mid-stage clinical programs, most notably TNX‑102 SL, a sublingual formulation of cyclobenzaprine for fibromyalgia and PTSD, and TNX‑801, a live-virus vaccine candidate for smallpox and mpox. Tonix positions itself strategically at the intersection of CNS therapeutics and government-supported biodefense initiatives, leveraging regulatory pathways and non-dilutive funding opportunities. Founded in 2007, Tonix has evolved from an early-stage CNS-focused company into a diversified pipeline developer with expanded emphasis on infectious disease preparedness.
Business Operations
Tonix conducts its operations through several internal business units, including Tonix Medicines, Tonix Vaccines, and Tonix Defense, which collectively manage its therapeutic and vaccine development activities. The company does not currently generate product revenue and instead operates as a development-stage enterprise, funding operations primarily through equity financings, government grants, and strategic collaborations.
Research and development activities are largely outsourced to contract research organizations, while strategic oversight, intellectual property management, and regulatory strategy are maintained internally. Tonix maintains a portfolio of owned and licensed technologies, including proprietary formulations and live-virus vaccine platforms. The company has pursued partnerships and funding relationships with U.S. government agencies for biodefense-related programs; however, details on long-term commercial partnerships remain limited based on publicly available disclosures.
Strategic Position & Investments
Tonix’s strategic direction emphasizes advancing TNX‑102 SL toward potential regulatory approval while expanding its infectious disease and biodefense pipeline. The company has invested significantly in its vaccine platform, particularly TNX‑801, which targets orthopoxviruses and is positioned for potential use in national stockpiling efforts. These programs align with increased government and public health focus on pandemic preparedness.
In addition to internal development, Tonix has pursued selective acquisitions and licensing agreements to expand its intellectual property base. Notable investments include assets supporting its vaccine manufacturing and development capabilities. The company continues to explore emerging areas such as broad-spectrum antivirals and immune-modulating therapies, although some programs remain in preclinical or early clinical stages, and outcomes are uncertain based on available public sources.
Geographic Footprint
Tonix is headquartered in Chatham, New Jersey, and its operations are primarily based in the United States. The company’s executive leadership, corporate governance, and strategic planning functions are centralized at its U.S. headquarters.
While Tonix does not maintain extensive international commercial operations, its clinical trials, regulatory engagements, and biodefense initiatives have global relevance, particularly in addressing infectious disease threats. The company’s vaccine and antiviral programs are designed for potential deployment across North America, Europe, and other regions through government or multilateral public health channels.
Leadership & Governance
Tonix is led by a founder-driven management team with experience in biotechnology, CNS drug development, and regulatory affairs. The leadership emphasizes scientific rigor, capital efficiency, and alignment with public health priorities, particularly in CNS disorders and biodefense.
Key executives include:
- Seth Lederman, M.D. – Chairman of the Board, President, and Chief Executive Officer
- Gregory Sullivan – Chief Operating Officer
- Jenipher Kim – Chief Financial Officer
- Susan F. Schiller, Ph.D. – Executive Vice President, Research and Development
The board and management team collectively guide Tonix’s long-term strategy, balancing late-stage clinical execution with opportunistic investment in emerging therapeutic and vaccine technologies. Some executive role details may vary over time; data inconclusive based on available public sources for the most recent changes.